Hematology
Lymphopenia
7
Pipeline Programs↗
2
Active Trials↗
5
Companies Involved↗
Lymphopenia is an early-stage landscape with 7 programs across 5 companies. The most active players are Glaxo Dba Glaxosmithkline, Eastern Cooperative Oncology Group, Genzyme, a Sanofi Company. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 22
Phase 3
No programs
Approved1
Analysis
Modality Breakdown
8programs
Small molecule338%
Protein / enzyme338%
Monoclonal antibody113%
Cell therapy113%
Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
7
clinical trials
Completed4 · 57%
Recruiting2 · 29%
Available1 · 14%
Clinical Trials
Trial Activity
7 trials
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04097561·20 enrolled
Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19
Completed·—·N/A·NCT04910230·24 enrolled
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer
Completed·—·Phase 1·NCT00693095·23 enrolled
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
Completed·IInstituto de Investigación Hospital Universitario La Paz·Phase 1/2·NCT04578210·84 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)